Home › Atopic Dermatitis (Eczema) › Florida
Pag-aaral pangklinika para sa Atopic Dermatitis (Eczema) sa Florida
18 pag-aaral para sa Atopic Dermatitis (Eczema) ang naghahanap ng mga kalahok sa mga site sa Florida.
Mga Lungsod sa Florida
- Miami9 pag-aaral
- Tampa7 pag-aaral
- St. Petersburg5 pag-aaral
- Coral Springs4 pag-aaral
- Miami Gardens4 pag-aaral
- Jacksonville3 pag-aaral
- Kendall3 pag-aaral
- Boca Raton3 pag-aaral
- Hollywood3 pag-aaral
Opisyal na teksto ng pag-aaral (English)
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
- Clinical Site 110, Miami
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07453602This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- St. Jude Clinical Research- Site Number : 8400049, Doral
- Ziaderm Research, LLC- Site Number : 8400021, North Miami Beach
Nagre-recruitObservasyonal na pag-aaral
Edad 12 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Miami
- Novartis Investigative Site, St. Petersburg
Nagre-recruitPhase 2
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06947993A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
- Gsi Clinical Research, Margate
Nagre-recruitPhase 2
Edad 18 hanggang 64 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07216027A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Solutions Through Advanced Research, Jacksonville
Nagre-recruitPhase 3
Edad 2 hanggang 11 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06807281Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Fort Lauderdale
- Enveda Investigative Site, Miami
- Enveda Investigative Site, Miramar
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07298395A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Coral Gables
- Investigational Site, Jacksonville
- Investigational Site, Margate
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07003425A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
- AllerVie Clinical Research, Panama City
- GCP Research , Global Clinical Professionals, St. Petersburg
Nagre-recruitPhase 3
Edad 12 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07765888A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
- Olympian Clinical Research, Tampa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07223697A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- ABMED Clinical Research Corp., Cape Coral
- Skin Care Research, Hollywood
- Quality Care Clinical Research, Miami
- at 4 pa
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07599813A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 19, Ocala
- Inmagene Site 4, Tampa
Nagre-recruitPhase 2
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT07037901A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Pediatric Skin Research - Coral Gables /ID# 266308, Coral Gables
Nagre-recruitPhase 3
Edad 2 hanggang 11 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06461897A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Boca Raton
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT07643766FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- Miami Dermatology and Laser Research, Miami
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT06564389A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Jacksonville
- Leo Pharma Investigational site, Miami
- Leo Pharma Investigational site, Tampa
Nagre-recruitPhase 3
6 Months – 11 Years · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Skin Care Research Boca Raton /ID# 263733, Boca Raton
- TrueBlue Clinical Research - Brandon /ID# 265037, Brandon
- Life Clinical Trials - Coral Springs /ID# 267195, Coral Springs
- at 13 pa
Nagre-recruitPhase 3
Edad 18 hanggang 63 · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Revival Research, Doral
- Floridian Research Institute Llc, Miami
- Global Health Research Center, Inc., Miami Lakes
- at 4 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 4, 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 8597, Boca Raton
- Galderma Investigational Site 7087, Coral Gables
- Galderma Investigational Site 7063, Cutler Bay
- at 7 pa
Nagre-recruitObservasyonal na pag-aaral
Edad 12 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT06988605Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.